Physician profile
Mark A Johnson
NPI 1205803418
$607.50
in general payments reported to CMS, 2019-2025
9 companies · $17.44 in 2025
The $17.44 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.52 · 2020: $39.72 · 2021: $43.52 · 2022: $45.27 · 2023: $187 · 2024: $253 · 2025: $17.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $207.21 | 2023-2024 | Clareon |
| Johnson & Johnson Surgical Vision, INC. | $205.05 | 2021-2023 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.95 | 2019-2020 | |
| Harrow Eye, LLC | $35.72 | 2024-2025 | Vevye |
| Allergan, INC. | $30.76 | 2021-2022 | |
| Astellas Pharma US INC | $28.09 | 2024 | Izervay |
| Takeda Pharmaceuticals U.S.A., INC. | $23.30 | 2024 | Iclusig |
| Sight Sciences, INC. | $21.29 | 2020 | |
| Bausch & Lomb Americas INC. | $16.13 | 2023 | Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.